Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis: The impact of genome-wide association studies identified disease risk loci

Olga Kulakova, Vitalina Bashinskaya, Ivan Kiselev, Natalia Baulina, Ekaterina Tsareva, Ruslan Nikolaev, Maxim Kozin, Sergey Shchur, Alexander Favorov, Alexey Boyko, Olga Favorova

Research output: Contribution to journalArticle

Abstract

Aim: Association analysis of genome-wide association studies (GWAS) identified multiple sclerosis (MS) risk genetic variants with glatiramer acetate (GA) treatment efficacy. Patients & methods: SNPs in 17 GWAS-identified immune response loci were analyzed in 296 Russian MS patients as possible markers of optimal GA treatment response for at least 2 years. Results: Alleles/genotypes of EOMES, CLEC16A, IL22RA2, PVT1 and HLA-DRB1 were associated by themselves with event-free phenotype during GA treatment for at least 2 years (p f = 0.032-0.00092). The biallelic combinations including EOMES, CLEC16A, IL22RA2, PVT1, TYK2, CD6, IL7RA and IRF8 genes were associated with response to GA with increased significance level (p f = 0.0060-1.1 × 10- 5). The epistasic interactions or additive effects were observed between the components of the identified biallelic combinations. Conclusion: We pinpointed the involvement of several GWAS-identified MS risk loci in GA therapy efficacy. These findings may be aggregated to predict the optimal GA response in MS patients.

Original languageEnglish (US)
Pages (from-to)1563-1574
Number of pages12
JournalPharmacogenomics
Volume18
Issue number17
DOIs
StatePublished - Nov 1 2017

Fingerprint

Genome-Wide Association Study
Pharmacogenetics
Multiple Sclerosis
Therapeutics
HLA-DRB1 Chains
Single Nucleotide Polymorphism
Glatiramer Acetate
Alleles
Genotype
Phenotype
Genes

Keywords

  • biomarker
  • copaxone
  • epistasis
  • glatiramer acetate
  • GWAS
  • multiple sclerosis
  • pharmacogenomics
  • polymorphism
  • SNP

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

Kulakova, O., Bashinskaya, V., Kiselev, I., Baulina, N., Tsareva, E., Nikolaev, R., ... Favorova, O. (2017). Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis: The impact of genome-wide association studies identified disease risk loci. Pharmacogenomics, 18(17), 1563-1574. https://doi.org/10.2217/pgs-2017-0058

Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis : The impact of genome-wide association studies identified disease risk loci. / Kulakova, Olga; Bashinskaya, Vitalina; Kiselev, Ivan; Baulina, Natalia; Tsareva, Ekaterina; Nikolaev, Ruslan; Kozin, Maxim; Shchur, Sergey; Favorov, Alexander; Boyko, Alexey; Favorova, Olga.

In: Pharmacogenomics, Vol. 18, No. 17, 01.11.2017, p. 1563-1574.

Research output: Contribution to journalArticle

Kulakova, O, Bashinskaya, V, Kiselev, I, Baulina, N, Tsareva, E, Nikolaev, R, Kozin, M, Shchur, S, Favorov, A, Boyko, A & Favorova, O 2017, 'Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis: The impact of genome-wide association studies identified disease risk loci', Pharmacogenomics, vol. 18, no. 17, pp. 1563-1574. https://doi.org/10.2217/pgs-2017-0058
Kulakova, Olga ; Bashinskaya, Vitalina ; Kiselev, Ivan ; Baulina, Natalia ; Tsareva, Ekaterina ; Nikolaev, Ruslan ; Kozin, Maxim ; Shchur, Sergey ; Favorov, Alexander ; Boyko, Alexey ; Favorova, Olga. / Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis : The impact of genome-wide association studies identified disease risk loci. In: Pharmacogenomics. 2017 ; Vol. 18, No. 17. pp. 1563-1574.
@article{2f117905391040209700edb6ffd48556,
title = "Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis: The impact of genome-wide association studies identified disease risk loci",
abstract = "Aim: Association analysis of genome-wide association studies (GWAS) identified multiple sclerosis (MS) risk genetic variants with glatiramer acetate (GA) treatment efficacy. Patients & methods: SNPs in 17 GWAS-identified immune response loci were analyzed in 296 Russian MS patients as possible markers of optimal GA treatment response for at least 2 years. Results: Alleles/genotypes of EOMES, CLEC16A, IL22RA2, PVT1 and HLA-DRB1 were associated by themselves with event-free phenotype during GA treatment for at least 2 years (p f = 0.032-0.00092). The biallelic combinations including EOMES, CLEC16A, IL22RA2, PVT1, TYK2, CD6, IL7RA and IRF8 genes were associated with response to GA with increased significance level (p f = 0.0060-1.1 × 10- 5). The epistasic interactions or additive effects were observed between the components of the identified biallelic combinations. Conclusion: We pinpointed the involvement of several GWAS-identified MS risk loci in GA therapy efficacy. These findings may be aggregated to predict the optimal GA response in MS patients.",
keywords = "biomarker, copaxone, epistasis, glatiramer acetate, GWAS, multiple sclerosis, pharmacogenomics, polymorphism, SNP",
author = "Olga Kulakova and Vitalina Bashinskaya and Ivan Kiselev and Natalia Baulina and Ekaterina Tsareva and Ruslan Nikolaev and Maxim Kozin and Sergey Shchur and Alexander Favorov and Alexey Boyko and Olga Favorova",
year = "2017",
month = "11",
day = "1",
doi = "10.2217/pgs-2017-0058",
language = "English (US)",
volume = "18",
pages = "1563--1574",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "17",

}

TY - JOUR

T1 - Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis

T2 - The impact of genome-wide association studies identified disease risk loci

AU - Kulakova, Olga

AU - Bashinskaya, Vitalina

AU - Kiselev, Ivan

AU - Baulina, Natalia

AU - Tsareva, Ekaterina

AU - Nikolaev, Ruslan

AU - Kozin, Maxim

AU - Shchur, Sergey

AU - Favorov, Alexander

AU - Boyko, Alexey

AU - Favorova, Olga

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Aim: Association analysis of genome-wide association studies (GWAS) identified multiple sclerosis (MS) risk genetic variants with glatiramer acetate (GA) treatment efficacy. Patients & methods: SNPs in 17 GWAS-identified immune response loci were analyzed in 296 Russian MS patients as possible markers of optimal GA treatment response for at least 2 years. Results: Alleles/genotypes of EOMES, CLEC16A, IL22RA2, PVT1 and HLA-DRB1 were associated by themselves with event-free phenotype during GA treatment for at least 2 years (p f = 0.032-0.00092). The biallelic combinations including EOMES, CLEC16A, IL22RA2, PVT1, TYK2, CD6, IL7RA and IRF8 genes were associated with response to GA with increased significance level (p f = 0.0060-1.1 × 10- 5). The epistasic interactions or additive effects were observed between the components of the identified biallelic combinations. Conclusion: We pinpointed the involvement of several GWAS-identified MS risk loci in GA therapy efficacy. These findings may be aggregated to predict the optimal GA response in MS patients.

AB - Aim: Association analysis of genome-wide association studies (GWAS) identified multiple sclerosis (MS) risk genetic variants with glatiramer acetate (GA) treatment efficacy. Patients & methods: SNPs in 17 GWAS-identified immune response loci were analyzed in 296 Russian MS patients as possible markers of optimal GA treatment response for at least 2 years. Results: Alleles/genotypes of EOMES, CLEC16A, IL22RA2, PVT1 and HLA-DRB1 were associated by themselves with event-free phenotype during GA treatment for at least 2 years (p f = 0.032-0.00092). The biallelic combinations including EOMES, CLEC16A, IL22RA2, PVT1, TYK2, CD6, IL7RA and IRF8 genes were associated with response to GA with increased significance level (p f = 0.0060-1.1 × 10- 5). The epistasic interactions or additive effects were observed between the components of the identified biallelic combinations. Conclusion: We pinpointed the involvement of several GWAS-identified MS risk loci in GA therapy efficacy. These findings may be aggregated to predict the optimal GA response in MS patients.

KW - biomarker

KW - copaxone

KW - epistasis

KW - glatiramer acetate

KW - GWAS

KW - multiple sclerosis

KW - pharmacogenomics

KW - polymorphism

KW - SNP

UR - http://www.scopus.com/inward/record.url?scp=85034570783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034570783&partnerID=8YFLogxK

U2 - 10.2217/pgs-2017-0058

DO - 10.2217/pgs-2017-0058

M3 - Article

C2 - 29095108

AN - SCOPUS:85034570783

VL - 18

SP - 1563

EP - 1574

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 17

ER -